Third Harmonic Bio Inc
THRD
Company Profile
Business description
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company’s product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
Contact
1700 Montgomery Street
Suite 210
San FranciscoCA94111
USAT: +1 209 727-2457
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
51
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,683.40 | 55.00 | 0.64% |
| CAC 40 | 7,891.68 | 14.72 | -0.19% |
| DAX 40 | 21,585.93 | 80.23 | 0.37% |
| Dow JONES (US) | 44,817.66 | 395.75 | 0.89% |
| FTSE 100 | 8,623.29 | 52.52 | 0.61% |
| HKSE | 20,597.09 | 192.87 | -0.93% |
| NASDAQ | 19,647.22 | 6.79 | -0.03% |
| Nikkei 225 | 38,831.48 | 33.11 | 0.09% |
| NZX 50 Index | 12,844.59 | 60.45 | -0.47% |
| S&P 500 | 6,052.47 | 14.59 | 0.24% |
| S&P/ASX 200 | 8,416.90 | 37.50 | 0.45% |
| SSE Composite Index | 3,229.49 | 21.11 | -0.65% |